Delpor’s Implant Device

We are pleased to announce that our portfolio company Delpor was selected by the National Institutes of Health (NIH) to exhibit and showcase its technology at the 2017 International Convention of the Biotechnology Innovation Organization (BIO) in San Diego, CA, June 19 – 22. Delpor will be exhibiting at BIO’s Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing 60 NIH and 20 NSF SBIR/STTR awardees.

“We are honored to have been selected as one of the companies to exhibit at BIO’s Innovation Zone, and we are looking forward to having fruitful discussions with potential partners,” said Tassos Nicolaou, President and CEO of Delpor.

During the conference, Delpor will focus on its lead program, DLP-114 (6-month risperidone formulation for schizophrenia maintenance treatment) and on its two key implantable drug delivery technologies (PROZOR™ and NANOPOR™), and meet with several potential partners interested in its implantable drug delivery technologies, and its schizophrenia and diabetes programs.

“We are honored to have been selected as one of the companies to exhibit at BIO’s Innovation Zone, and we are looking forward to having fruitful discussions with potential partners”
– Tassos Nicolaou, President and CEO of Delpor

Delpor’s DLP-114 is a small titanium reservoir designed for subcutaneous implantation and loaded with a proprietary formulation of risperidone. The product is designed to provide a constant therapeutic dose of risperidone each day for a total period of 6 months. Additional features are expected to include reversibility, immediate onset of action, and no accumulation.